The National Institute for Health and Care Excellence (NICE) is not recommending Ponvory (ponesimod) is made available on the NHS in England and Wales for people with active, relapsing forms of multiple sclerosis (MS).
NICE’s decision currently applies to England and Wales, though Northern Ireland tends to follow the same guidance following a review. In Scotland, the Scottish Medicines Consortium will decide next month whether it will be available there on the NHS.
This is the second rejection of an oral drug for MS in just five months. NICE rejected Zeposia (ozanimod) in May for England and Wales, though it was approved for Scotland. NICE said it found neither treatment to be cost effective.
Anyone wishing to share their experience with the drug and how they think it would make a difference for those living with MS should email their opinions to firstname.lastname@example.org
Source: MS-UK 13 October 2021